...
首页> 外文期刊>Clinical & developmental immunology. >A Mycobacterium bovis BCG-Naked DNA Prime-Boost Vaccination Strategy Induced CD4~+ and CD8~+ T-Cell Response against Mycobacterium tuberculosis Immunogens
【24h】

A Mycobacterium bovis BCG-Naked DNA Prime-Boost Vaccination Strategy Induced CD4~+ and CD8~+ T-Cell Response against Mycobacterium tuberculosis Immunogens

机译:牛分枝杆菌BCG裸DNA初免-加强免疫策略诱导针对结核分枝杆菌免疫原的CD4〜+和CD8〜+ T细胞反应。

获取原文
获取原文并翻译 | 示例
           

摘要

Mycobacterium tuberculosis infection is still a major global public health problem. Presently the only tuberculosis (TB) vaccine available is Bacille Calmette-Guerin (BCG), although it fails to adequately protect against pulmonary TB in adults. To solve this problem, the development of a new effective vaccine is urgently desired. BCG-prime DNA-booster vaccinations strategy has been shown to induce greater protection against tuberculosis (TB) than BCG alone. Some studies have demonstrated that the two genes (Rvl769 and Rvl772) are excellent T-cell antigens and could induce T-cell immune responses. In this research, we built BCG-C or BCG-P prime-recombination plasmid PcDNA3.1-Rvl769 or PcDNA3.1-Rvl772 boost vaccinations strategy to immunize BALB/c mice and evaluated its immunogenicity. The data suggests that the BCG-C+3.1-72 strategy could elicit the most long-lasting and strongest Thl-type cellular immune responses and the BCG-C+3.1-69 strategy could induce the high level CD8+ T-cell response at certain time points. These findings support the ideas that the prime-boost strategy as a combination of vaccines may be better than a single vaccine for protection against tuberculosis.
机译:结核分枝杆菌感染仍然是全球主要的公共卫生问题。目前,可用的唯一结核病(TB)疫苗是Bacille Calmette-Guerin(BCG),尽管它不能充分保护成年人免受肺结核的侵害。为了解决这个问题,迫切需要开发一种新的有效疫苗。已经证明,与单独使用BCG相比,BCG-prime DNA-booster疫苗接种策略可带来更大的抗结核病(TB)保护作用。一些研究表明,这两个基因(Rvl769和Rvl772)是出色的T细胞抗原,可以诱导T细胞免疫反应。在这项研究中,我们建立了BCG-C或BCG-P初免重组质粒PcDNA3.1-Rvl769或PcDNA3.1-Rvl772加强免疫策略以免疫BALB / c小鼠,并评估了其免疫原性。数据表明,BCG-C + 3.1-72策略可引发最持久和最强的Thl型细胞免疫反应,而BCG-C + 3.1-69策略可在一定程度上诱导高水平CD8 + T细胞反应时间点。这些发现支持这样的观点,即初免-加强策略作为疫苗的组合可能比单一的针对结核病的疫苗更好。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号